NorthSea Therapeutics Unveils Positive Phase 2b ICONA Results for Icosabutate in MASH Treatment
Portfolio | Mar 06, 2025 | Ysios Capital
NorthSea Therapeutics announced promising results from its Phase 2b ICONA clinical trial of icosabutate for treating metabolic dysfunction-associated steatohepatitis (MASH), with significant improvements in fibrosis noted. NorthSea's advanced testing methods, including AI-assisted digital pathology, demonstrated icosabutate's unique mechanism of action that does not rely on reducing liver fat or body weight, positioning it effectively for combination therapies with incretin-based treatments. These results reinforce the potential of icosabutate as a monotherapy or combination therapy for more advanced MASH patients, especially those with underlying diabetes. NorthSea Therapy is a Netherlands-based biotechnology firm focused on novel strategies for treating metabolic, cholestatic, and fibrotic diseases. Their work, supported by notable investors including Ysios Capital and Forbion Growth, highlights the innovative edge in addressing severe unmet medical needs.
Sectors
- Biotechnology
- Healthcare
Geography
- Netherlands – NorthSea Therapeutics is headquartered in the Netherlands, where the clinical trials and company operations are centered.
- United States – NorthSea Therapeutics has a presence in the United States, potentially reflecting market interest and expansion in North American healthcare sectors.
Industry
- Biotechnology – The article focuses on NorthSea Therapeutics, a biotechnology company developing treatments for metabolic, cholestatic, and fibrotic diseases using advanced clinical trials.
- Healthcare – The clinical trial results pertain to healthcare advances, specifically in therapeutic treatments for liver-related illnesses like MASH and MASLD.
Financials
- $80M – Series C financing for NorthSea Therapeutics co-led by Ysios Capital and Forbion Growth.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NorthSea Therapeutics | Target Company | Company | A private, late-stage clinical biotechnology company developing treatments for metabolic, cholestatic, and fibrotic diseases. |
| Ysios Capital | Investor | Company | A private equity firm that provided significant funding support for NorthSea Therapeutics' projects. |
| Arun Sanyal, M.D. | Medical Expert | Person | Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health and key author of the publication. |